GE HEALTHCARE TECHNOLOGIES INC. (GEHC) Gross Margin
- Gross margin · 12 months: Value 39.15%; Formula and calculation Gross profit / revenue. Period ending 2026-03-31..
Gross margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 39.15% | Gross profit / revenue. Period ending 2026-03-31. $8.21B ÷ $20.98B × 100 ≈ 39.15% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 8.21B USD | Gross Profit |
| Revenue | 20.98B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-03-31 | $8.21B | $20.98B | (m) | 39.15% |
| 2025-12-31 | $8.25B | $20.63B | (m) | 39.99% |
| 2025-09-30 | $8.26B | $20.25B | (m) | 40.81% |
| 2025-06-30 | $8.30B | $19.97B | (m) | 41.56% |
| 2025-03-31 | $8.31B | $19.80B | (m) | 42.00% |
| 2024-12-31 | $8.21B | $19.67B | (m) | 41.71% |
| 2024-09-30 | $8.09B | $19.56B | (m) | 41.34% |
| 2024-06-30 | $8.00B | $19.52B | (m) | 40.96% |
| 2024-03-31 | $7.93B | $19.50B | (m) | 40.69% |
| 2023-12-31 | $7.92B | $19.55B | (m) | 40.52% |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | $7.18B | $18.34B | (m) | 39.14% |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | $7.17B | $17.59B | (m) | 40.80% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.